糖尿病心血管并发症患者AGEs与NO的变化特点及其临床意义

The clinical significance and variation characteristic of AGEs and NO in cardiovascular complications in patients with DM

目的探讨糖尿病(DM)时AGEs与NO的关系,以及AGEs与NO在糖尿病心血管并发症中的意义。方法用ELISA法检测研究对象血清中AGEs的水平,用硝酸还原酶法检测研究对象血清中NO含量。结果①糖尿病患者清AGEs水平高于健康对照组,且糖尿病有心血管并发症组AGEs明显高于无心血管并发症组。②糖尿病患者血清NO水平低于健康对照组,且糖尿病有心血管并发症组NO明显低于无心血管并发症组。③AGEs与NO呈负相关。结论血中高浓度的AGEs可能通过灭活NO等机制与NO共同参与DM心血管并发症的发生发展。

Objective To determine the role and mechanism of advanced glycafion end products（AGEs）and NO in cardiovascular complications in patients with DM and the interaction between AGEs and NO.Methods The study population were divided into two groups.One group is a normal control and another group is a DM group, DM group were divided into two groups with or without cardiovascular complications.By using a competitive ELISA, we measured the AGEs levels, meanwhile, measured NO activities. Results ①Compared with normal control group, the serum AGEs level with DM group significantly increased（ P 〈 0.05） ;the serum AGEs in patients in patients with cardiovascular complications were significantly higher than in those without cardiovnscular complications（ P 〈 0.05 ）. ②Compared with normal control group, the serum NO activies with DM group significantly dee, lined （ P 〈 0.05） ; the serum NO activies in patients with cardiovascular complications were significantly lower than in those without cardionnserlar complications（ P 〈 0.05） .③In patients with DM, asignificantly negative conelafion was found between serum NO and AGE（ P 〈 0.05）. Those indicated that one of mechanisms of AGEs modulating cardiovascular complications is to quench NO. AGEs and NO initiafi and/or exacerbate cardiovascular complicafions with DM.